25 XP   0   0   10

Prostatype Genomics AB
Buy, Hold or Sell?

Let's analyse Prostatype Genomics AB together

PenkeI guess you are interested in Prostatype Genomics AB. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Prostatype Genomics AB. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Prostatype Genomics AB

I send you an email if I find something interesting about Prostatype Genomics AB.

Quick analysis of Prostatype Genomics AB (30 sec.)










What can you expect buying and holding a share of Prostatype Genomics AB? (30 sec.)

How much money do you get?

How much money do you get?
kr0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
kr0.03
Expected worth in 1 year
kr0.02
How sure are you?
57.1%

+ What do you gain per year?

Total Gains per Share
kr-0.01
Return On Investment
-12.1%

For what price can you sell your share?

Current Price per Share
kr0.06
Expected price per share
kr0.04 - kr0.22586901763224
How sure are you?
50%

1. Valuation of Prostatype Genomics AB (5 min.)




Live pricePrice per Share (EOD)

kr0.06

Intrinsic Value Per Share

kr-0.57 - kr-0.52

Total Value Per Share

kr-0.54 - kr-0.49

2. Growth of Prostatype Genomics AB (5 min.)




Is Prostatype Genomics AB growing?

Current yearPrevious yearGrowGrow %
How rich?$2.3m$2.4m-$138.8k-6.0%

How much money is Prostatype Genomics AB making?

Current yearPrevious yearGrowGrow %
Making money-$3.8m-$2.7m-$1.1m-29.8%
Net Profit Margin-3,055.7%-4,259.9%--

How much money comes from the company's main activities?

3. Financial Health of Prostatype Genomics AB (5 min.)




4. Comparing to competitors in the Diagnostics & Research industry (5 min.)




  Industry Rankings (Diagnostics & Research)  


Richest
#125 / 148

Most Revenue
#139 / 148

Most Profit
#92 / 148

Most Efficient
#140 / 148

What can you expect buying and holding a share of Prostatype Genomics AB? (5 min.)

Welcome investor! Prostatype Genomics AB's management wants to use your money to grow the business. In return you get a share of Prostatype Genomics AB.

What can you expect buying and holding a share of Prostatype Genomics AB?

First you should know what it really means to hold a share of Prostatype Genomics AB. And how you can make/lose money.

Speculation

The Price per Share of Prostatype Genomics AB is kr0.062. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Prostatype Genomics AB.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Prostatype Genomics AB, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is kr0.03. Based on the TTM, the Book Value Change Per Share is kr0.00 per quarter. Based on the YOY, the Book Value Change Per Share is kr-0.01 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is kr0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Prostatype Genomics AB.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 kr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Share
Usd Eps0.00-8.0%0.00-8.0%0.00-5.6%0.00-4.2%0.00-3.5%
Usd Book Value Change Per Share0.00-0.3%0.00-0.3%0.00-1.9%0.000.6%0.000.7%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.00-0.3%0.00-0.3%0.00-1.9%0.000.6%0.000.7%
Usd Price Per Share0.01-0.01-0.20-0.48-0.34-
Price to Earnings Ratio-1.81--1.81--57.45--266.75--190.53-
Price-to-Total Gains Ratio-50.70--50.70--171.32-318.57-318.57-
Price to Book Ratio3.04-3.04-63.90-132.33-94.52-
Price-to-Total Gains Ratio-50.70--50.70--171.32-318.57-318.57-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.005828
Number of shares171585
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.000.00
Usd Total Gains Per Share0.000.00
Gains per Quarter (171585 shares)-30.2266.00
Gains per Year (171585 shares)-120.89263.99
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-121-1310264254
20-242-2520528518
30-363-3730792782
40-484-494010561046
50-604-615013201310
60-725-736015841574
70-846-857018481838
80-967-978021122102
90-1088-1099023762366
100-1209-1220026402630

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.07.00.00.0%0.07.00.00.0%
Book Value Change Per Share0.01.00.00.0%1.02.00.033.3%2.02.01.040.0%4.02.01.057.1%4.02.01.057.1%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%0.00.07.00.0%0.00.07.00.0%
Total Gains per Share0.01.00.00.0%1.02.00.033.3%2.02.01.040.0%4.02.01.057.1%4.02.01.057.1%

Fundamentals of Prostatype Genomics AB

About Prostatype Genomics AB

Prostatype Genomics AB manufactures, markets, and sells the prognostic gene tests. It offers Prostatype Test System that combines gene expression information with used clinical parameters, such as PSA, Gleason Score, and Tumor Stage, as well as calculates the P-score. The company's test is based on database containing prostate cancer patients, as well as provides decision support for patients and doctors when making a treatment decision. Prostatype Genomics AB (publ) was incorporated in 2007 and is based in Solna, Sweden.

Fundamental data was last updated by Penke on 2024-03-12 11:26:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Prostatype Genomics AB.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Prostatype Genomics AB earns for each kr1 of revenue.

  • Above 10% is considered healthy but always compare Prostatype Genomics AB to the Diagnostics & Research industry mean.
  • A Net Profit Margin of -3,055.7% means that kr-30.56 for each kr1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Prostatype Genomics AB:

  • The MRQ is -3,055.7%. The company is making a huge loss. -2
  • The TTM is -3,055.7%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-3,055.7%TTM-3,055.7%0.0%
TTM-3,055.7%YOY-4,259.9%+1,204.2%
TTM-3,055.7%5Y-33,228.6%+30,172.9%
5Y-33,228.6%10Y-26,205.1%-7,023.5%
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ-3,055.7%-5.2%-3,050.5%
TTM-3,055.7%-6.0%-3,049.7%
YOY-4,259.9%-1.8%-4,258.1%
5Y-33,228.6%-8.0%-33,220.6%
10Y-26,205.1%-4.4%-26,200.7%
1.1.2. Return on Assets

Shows how efficient Prostatype Genomics AB is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Prostatype Genomics AB to the Diagnostics & Research industry mean.
  • -84.2% Return on Assets means that Prostatype Genomics AB generated kr-0.84 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Prostatype Genomics AB:

  • The MRQ is -84.2%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -84.2%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-84.2%TTM-84.2%0.0%
TTM-84.2%YOY-94.0%+9.8%
TTM-84.2%5Y-63.9%-20.3%
5Y-63.9%10Y-59.3%-4.6%
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ-84.2%-0.9%-83.3%
TTM-84.2%-0.8%-83.4%
YOY-94.0%-1.3%-92.7%
5Y-63.9%-1.2%-62.7%
10Y-59.3%-0.8%-58.5%
1.1.3. Return on Equity

Shows how efficient Prostatype Genomics AB is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Prostatype Genomics AB to the Diagnostics & Research industry mean.
  • -167.9% Return on Equity means Prostatype Genomics AB generated kr-1.68 for each kr1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Prostatype Genomics AB:

  • The MRQ is -167.9%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -167.9%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-167.9%TTM-167.9%0.0%
TTM-167.9%YOY-111.2%-56.7%
TTM-167.9%5Y-97.7%-70.2%
5Y-97.7%10Y-105.5%+7.8%
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ-167.9%-0.4%-167.5%
TTM-167.9%-0.3%-167.6%
YOY-111.2%-1.0%-110.2%
5Y-97.7%-1.7%-96.0%
10Y-105.5%-2.1%-103.4%

1.2. Operating Efficiency of Prostatype Genomics AB.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Prostatype Genomics AB is operating .

  • Measures how much profit Prostatype Genomics AB makes for each kr1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Prostatype Genomics AB to the Diagnostics & Research industry mean.
  • An Operating Margin of -2,898.7% means the company generated kr-28.99  for each kr1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Prostatype Genomics AB:

  • The MRQ is -2,898.7%. The company is operating very inefficient. -2
  • The TTM is -2,898.7%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-2,898.7%TTM-2,898.7%0.0%
TTM-2,898.7%YOY-4,201.9%+1,303.2%
TTM-2,898.7%5Y-32,999.5%+30,100.9%
5Y-32,999.5%10Y-25,895.7%-7,103.8%
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ-2,898.7%-9.4%-2,889.3%
TTM-2,898.7%-0.1%-2,898.6%
YOY-4,201.9%3.3%-4,205.2%
5Y-32,999.5%0.3%-32,999.8%
10Y-25,895.7%-2.7%-25,893.0%
1.2.2. Operating Ratio

Measures how efficient Prostatype Genomics AB is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Diagnostics & Research industry mean).
  • An Operation Ratio of 29.99 means that the operating costs are kr29.99 for each kr1 in net sales.

Let's take a look of the Operating Ratio trends of Prostatype Genomics AB:

  • The MRQ is 29.987. The company is inefficient in keeping operating costs low. -1
  • The TTM is 29.987. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ29.987TTM29.9870.000
TTM29.987YOY80.777-50.790
TTM29.9875Y338.347-308.360
5Y338.34710Y265.211+73.136
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ29.9871.315+28.672
TTM29.9871.297+28.690
YOY80.7771.277+79.500
5Y338.3471.246+337.101
10Y265.2111.215+263.996

1.3. Liquidity of Prostatype Genomics AB.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Prostatype Genomics AB is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Diagnostics & Research industry mean).
  • A Current Ratio of 1.06 means the company has kr1.06 in assets for each kr1 in short-term debts.

Let's take a look of the Current Ratio trends of Prostatype Genomics AB:

  • The MRQ is 1.058. The company is just able to pay all its short-term debts.
  • The TTM is 1.058. The company is just able to pay all its short-term debts.
Trends
Current periodCompared to+/- 
MRQ1.058TTM1.0580.000
TTM1.058YOY3.270-2.212
TTM1.0585Y3.065-2.007
5Y3.06510Y2.789+0.276
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ1.0582.183-1.125
TTM1.0582.341-1.283
YOY3.2702.625+0.645
5Y3.0652.989+0.076
10Y2.7892.958-0.169
1.3.2. Quick Ratio

Measures if Prostatype Genomics AB is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Prostatype Genomics AB to the Diagnostics & Research industry mean.
  • A Quick Ratio of 1.93 means the company can pay off kr1.93 for each kr1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Prostatype Genomics AB:

  • The MRQ is 1.928. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 1.928. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ1.928TTM1.9280.000
TTM1.928YOY4.770-2.842
TTM1.9285Y3.997-2.069
5Y3.99710Y3.404+0.592
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ1.9281.310+0.618
TTM1.9281.437+0.491
YOY4.7701.764+3.006
5Y3.9971.952+2.045
10Y3.4042.080+1.324

1.4. Solvency of Prostatype Genomics AB.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Prostatype Genomics AB assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Prostatype Genomics AB to Diagnostics & Research industry mean.
  • A Debt to Asset Ratio of 0.50 means that Prostatype Genomics AB assets are financed with 49.9% credit (debt) and the remaining percentage (100% - 49.9%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Prostatype Genomics AB:

  • The MRQ is 0.499. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.499. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.499TTM0.4990.000
TTM0.499YOY0.155+0.344
TTM0.4995Y0.287+0.212
5Y0.28710Y0.376-0.089
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4990.432+0.067
TTM0.4990.431+0.068
YOY0.1550.377-0.222
5Y0.2870.443-0.156
10Y0.3760.446-0.070
1.4.2. Debt to Equity Ratio

Measures if Prostatype Genomics AB is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Prostatype Genomics AB to the Diagnostics & Research industry mean.
  • A Debt to Equity ratio of 99.5% means that company has kr0.99 debt for each kr1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Prostatype Genomics AB:

  • The MRQ is 0.995. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.995. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.995TTM0.9950.000
TTM0.995YOY0.184+0.811
TTM0.9955Y0.509+0.486
5Y0.50910Y0.824-0.315
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ0.9950.606+0.389
TTM0.9950.595+0.400
YOY0.1840.603-0.419
5Y0.5090.636-0.127
10Y0.8240.730+0.094

2. Market Valuation of Prostatype Genomics AB

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every kr1 in earnings Prostatype Genomics AB generates.

  • Above 15 is considered overpriced but always compare Prostatype Genomics AB to the Diagnostics & Research industry mean.
  • A PE ratio of -1.81 means the investor is paying kr-1.81 for every kr1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Prostatype Genomics AB:

  • The EOD is -1.180. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.807. Based on the earnings, the company is expensive. -2
  • The TTM is -1.807. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.180MRQ-1.807+0.628
MRQ-1.807TTM-1.8070.000
TTM-1.807YOY-57.455+55.648
TTM-1.8075Y-266.748+264.940
5Y-266.74810Y-190.534-76.214
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
EOD-1.180-0.300-0.880
MRQ-1.807-0.567-1.240
TTM-1.807-0.341-1.466
YOY-57.455-0.242-57.213
5Y-266.748-0.129-266.619
10Y-190.5343.396-193.930
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Prostatype Genomics AB:

  • The EOD is -1.296. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.986. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -1.986. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.296MRQ-1.986+0.690
MRQ-1.986TTM-1.9860.000
TTM-1.986YOY-60.345+58.359
TTM-1.9865Y-213.792+211.805
5Y-213.79210Y-152.708-61.083
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
EOD-1.296-0.460-0.836
MRQ-1.986-0.918-1.068
TTM-1.986-1.763-0.223
YOY-60.345-3.236-57.109
5Y-213.792-2.150-211.642
10Y-152.708-3.427-149.281
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Prostatype Genomics AB is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Diagnostics & Research industry mean).
  • A PB ratio of 3.04 means the investor is paying kr3.04 for each kr1 in book value.

Let's take a look of the Price to Book Ratio trends of Prostatype Genomics AB:

  • The EOD is 1.981. Based on the equity, the company is underpriced. +1
  • The MRQ is 3.035. Based on the equity, the company is fair priced.
  • The TTM is 3.035. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD1.981MRQ3.035-1.054
MRQ3.035TTM3.0350.000
TTM3.035YOY63.904-60.869
TTM3.0355Y132.332-129.297
5Y132.33210Y94.523+37.809
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
EOD1.9812.021-0.040
MRQ3.0352.140+0.895
TTM3.0352.126+0.909
YOY63.9043.071+60.833
5Y132.3323.399+128.933
10Y94.5234.152+90.371
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Prostatype Genomics AB compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.002-0.0020%-0.012+560%0.004-146%0.004-142%
Book Value Per Share--0.0310.0310%0.033-6%0.0310%0.025+25%
Current Ratio--1.0581.0580%3.270-68%3.065-65%2.789-62%
Debt To Asset Ratio--0.4990.4990%0.155+222%0.287+74%0.376+33%
Debt To Equity Ratio--0.9950.9950%0.184+442%0.509+96%0.824+21%
Dividend Per Share----0%-0%-0%-0%
Eps---0.053-0.0530%-0.037-30%-0.028-48%-0.023-56%
Free Cash Flow Per Share---0.048-0.0480%-0.035-27%-0.028-42%-0.024-50%
Free Cash Flow To Equity Per Share---0.011-0.0110%-0.011+1%0.002-646%0.000-23406%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---0.519--------
Intrinsic Value_10Y_min---0.570--------
Intrinsic Value_1Y_max---0.033--------
Intrinsic Value_1Y_min---0.041--------
Intrinsic Value_3Y_max---0.114--------
Intrinsic Value_3Y_min---0.139--------
Intrinsic Value_5Y_max---0.212--------
Intrinsic Value_5Y_min---0.251--------
Market Cap48873732.992-53%74887171.52074887171.5200%1671166353.920-96%4013116810.295-98%2866512007.354-97%
Net Profit Margin---30.557-30.5570%-42.599+39%-332.286+987%-262.051+758%
Operating Margin---28.987-28.9870%-42.019+45%-329.995+1038%-258.957+793%
Operating Ratio--29.98729.9870%80.777-63%338.347-91%265.211-89%
Pb Ratio1.981-53%3.0353.0350%63.904-95%132.332-98%94.523-97%
Pe Ratio-1.180+35%-1.807-1.8070%-57.455+3079%-266.748+14659%-190.534+10442%
Price Per Share0.062-53%0.0950.0950%2.120-96%5.091-98%3.636-97%
Price To Free Cash Flow Ratio-1.296+35%-1.986-1.9860%-60.345+2938%-213.792+10663%-152.708+7588%
Price To Total Gains Ratio-33.089+35%-50.701-50.7010%-171.317+238%318.572-116%318.572-116%
Quick Ratio--1.9281.9280%4.770-60%3.997-52%3.404-43%
Return On Assets---0.842-0.8420%-0.940+12%-0.639-24%-0.593-30%
Return On Equity---1.679-1.6790%-1.112-34%-0.977-42%-1.055-37%
Total Gains Per Share---0.002-0.0020%-0.012+560%0.004-146%0.004-142%
Usd Book Value--2319356.0002319356.0000%2458197.008-6%2323073.0230%1857670.595+25%
Usd Book Value Change Per Share--0.0000.0000%-0.001+560%0.000-146%0.000-142%
Usd Book Value Per Share--0.0030.0030%0.003-6%0.0030%0.002+25%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.005-0.0050%-0.003-30%-0.003-48%-0.002-56%
Usd Free Cash Flow---3543800.000-3543800.0000%-2603177.908-27%-2053204.062-42%-1778963.791-50%
Usd Free Cash Flow Per Share---0.004-0.0040%-0.003-27%-0.003-42%-0.002-50%
Usd Free Cash Flow To Equity Per Share---0.001-0.0010%-0.001+1%0.000-646%0.000-23406%
Usd Market Cap4594130.901-53%7039394.1237039394.1230%157089637.268-96%377232980.168-98%269452128.691-97%
Usd Price Per Share0.006-53%0.0090.0090%0.199-96%0.479-98%0.342-97%
Usd Profit---3894890.000-3894890.0000%-2734134.102-30%-2114551.131-46%-1750280.712-55%
Usd Revenue--127464.000127464.0000%64183.012+99%51374.328+148%39864.124+220%
Usd Total Gains Per Share--0.0000.0000%-0.001+560%0.000-146%0.000-142%
 EOD+3 -5MRQTTM+0 -0YOY+14 -195Y+6 -2710Y+9 -24

3.2. Fundamental Score

Let's check the fundamental score of Prostatype Genomics AB based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.180
Price to Book Ratio (EOD)Between0-11.981
Net Profit Margin (MRQ)Greater than0-30.557
Operating Margin (MRQ)Greater than0-28.987
Quick Ratio (MRQ)Greater than11.928
Current Ratio (MRQ)Greater than11.058
Debt to Asset Ratio (MRQ)Less than10.499
Debt to Equity Ratio (MRQ)Less than10.995
Return on Equity (MRQ)Greater than0.15-1.679
Return on Assets (MRQ)Greater than0.05-0.842
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of Prostatype Genomics AB based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5054.792
Ma 20Greater thanMa 500.058
Ma 50Greater thanMa 1000.052
Ma 100Greater thanMa 2000.060
OpenGreater thanClose0.054
Total2/5 (40.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. All numbers in thousands.

Summary
Total Assets49,222
Total Liabilities24,548
Total Stockholder Equity24,674
 As reported
Total Liabilities 24,548
Total Stockholder Equity+ 24,674
Total Assets = 49,222

Assets

Total Assets49,222
Total Current Assets25,910
Long-term Assets23,312
Total Current Assets
Cash And Cash Equivalents 2,682
Short-term Investments 21,493
Net Receivables 1,531
Inventory 203
Other Current Assets 1
Total Current Assets  (as reported)25,910
Total Current Assets  (calculated)25,910
+/-0
Long-term Assets
Property Plant Equipment 60
Long-term Assets Other 23,180
Long-term Assets  (as reported)23,312
Long-term Assets  (calculated)23,240
+/- 72

Liabilities & Shareholders' Equity

Total Current Liabilities24,481
Long-term Liabilities67
Total Stockholder Equity24,674
Total Current Liabilities
Other Current Liabilities 24,481
Total Current Liabilities  (as reported)24,481
Total Current Liabilities  (calculated)24,481
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)67
Long-term Liabilities  (calculated)0
+/- 67
Total Stockholder Equity
Common Stock7,168
Other Stockholders Equity 17,506
Total Stockholder Equity (as reported)24,674
Total Stockholder Equity (calculated)24,674
+/-0
Other
Cash and Short Term Investments 24,175
Common Stock Shares Outstanding 80,820
Liabilities and Stockholders Equity 49,222
Net Debt -2,615
Net Working Capital 1,429
Short Long Term Debt Total 67



Balance Sheet

All numbers in thousands.

 Trend2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
> Total Assets 
0
19,711
17,574
0
33,663
40,203
30,950
49,222
49,22230,95040,20333,663017,57419,7110
   > Total Current Assets 
11,170
9,701
4,476
9,443
17,456
21,585
14,169
25,910
25,91014,16921,58517,4569,4434,4769,70111,170
       Cash And Cash Equivalents 
0
8,209
2,692
0
15,862
9,829
4,811
2,682
2,6824,8119,82915,86202,6928,2090
       Short-term Investments 
0
0
0
0
0
10,500
6,678
21,493
21,4936,67810,50000000
       Net Receivables 
247
1,116
1,120
332
1,199
1,074
2,498
1,531
1,5312,4981,0741,1993321,1201,116247
       Inventory 
347
376
664
388
395
108
44
203
20344108395388664376347
   > Long-term Assets 
0
10,011
13,098
0
16,206
18,618
16,781
23,312
23,31216,78118,61816,206013,09810,0110
       Property Plant Equipment 
213
92
40
35
28
14
4
60
6041428354092213
       Intangible Assets 
0
9,898
13,058
0
0
18,604
16,710
0
016,71018,6040013,0589,8980
       Long-term Assets Other 
0
20
0
0
16,178
0
6,678
23,180
23,1806,678016,17800200
> Total Liabilities 
0
13,488
9,027
0
5,372
4,297
4,799
24,548
24,5484,7994,2975,37209,02713,4880
   > Total Current Liabilities 
2,761
3,938
2,575
14,545
4,306
3,430
4,333
24,481
24,4814,3333,4304,30614,5452,5753,9382,761
       Short-term Debt 
0
26
400
0
400
400
400
0
04004004000400260
       Short Long Term Debt 
0
26
400
0
0
400
400
0
040040000400260
       Accounts payable 
997
1,176
653
962
1,779
1,175
2,184
0
02,1841,1751,7799626531,176997
       Other Current Liabilities 
1,179
265
118
11,867
2,071
212
461
24,481
24,4814612122,07111,8671182651,179
   > Long-term Liabilities 
0
9,550
6,452
0
1,067
867
467
67
674678671,06706,4529,5500
       Other Liabilities 
0
0
0
0
0
0
0
0
00000000
> Total Stockholder Equity
0
6,223
8,546
0
28,290
35,906
26,151
24,674
24,67426,15135,90628,29008,5466,2230
   Common Stock
851
1,021
1,021
558
791
905
1,372
7,168
7,1681,3729057915581,0211,021851
   Retained Earnings Total Equity00000000
   Accumulated Other Comprehensive Income 
0
0
13,475
0
16,067
18,566
16,710
0
016,71018,56616,067013,47500
   Capital Surplus 00000000
   Treasury Stock00000000
   Other Stockholders Equity 
12,738
69,974
70,602
0
107,322
130,453
149,318
17,506
17,506149,318130,453107,322070,60269,97412,738



Balance Sheet

All numbers in thousands.




Cash Flow

Currency in SEK. All numbers in thousands.




Income Statement

All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue1,356
Cost of Revenue-37,437
Gross Profit-36,081-36,081
 
Operating Income (+$)
Gross Profit-36,081
Operating Expense-3,225
Operating Income-39,306-39,306
 
Operating Expense (+$)
Research Development3,225
Selling General Administrative0
Selling And Marketing Expenses0
Operating Expense3,2253,225
 
Net Interest Income (+$)
Interest Income0
Interest Expense-1,540
Other Finance Cost-1,540
Net Interest Income0
 
Pretax Income (+$)
Operating Income-39,306
Net Interest Income0
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-41,435-37,177
EBIT - interestExpense = -40,846
-41,435
-39,895
Interest Expense1,540
Earnings Before Interest and Taxes (EBIT)-39,306-39,895
Earnings Before Interest and Taxes (EBITDA)-37,431
 
After tax Income (+$)
Income Before Tax-41,435
Tax Provision-0
Net Income From Continuing Ops0-41,435
Net Income-41,435
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses40,662
Total Other Income/Expenses Net-2,1290
 

Technical Analysis of Prostatype Genomics AB
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Prostatype Genomics AB. The general trend of Prostatype Genomics AB is BEARISH with 28.6% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Prostatype Genomics AB's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-28.6%) Bearish trend (28.6%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Prostatype Genomics AB.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 0.069 < 0.22585078534031 < 0.22586901763224.

The bearish price targets are: 0.0418 > 0.04 > 0.04.

Tweet this
Prostatype Genomics AB Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Prostatype Genomics AB. The current mas is .

The long score for the Moving Averages is 5/14.
The longshort score for the Moving Averages is -4/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Prostatype Genomics AB Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Prostatype Genomics AB. The current macd is 0.00085449.

The long score for the Moving Average Convergence/Divergence (MACD) is 2/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 0/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Prostatype Genomics AB price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Prostatype Genomics AB. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Prostatype Genomics AB price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Prostatype Genomics AB Daily Moving Average Convergence/Divergence (MACD) ChartProstatype Genomics AB Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Prostatype Genomics AB. The current adx is 18.62.

The long score for the Directional Movement Index (DMI) is 2/7.
The longshort score for the Directional Movement Index (DMI) is 2/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Prostatype Genomics AB shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bullish trend could be forming. +1
Prostatype Genomics AB Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Prostatype Genomics AB. The current sar is 0.04592933.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Prostatype Genomics AB Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Prostatype Genomics AB. The current rsi is 54.79. The current phase is Correction in bear market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Correction in bear market: Extended price decline in a downtrend, significant pullback. Consider reducing exposure, wait for signs of trend reversal.
  • Trending up: The RSI is trending up. +1
Prostatype Genomics AB Daily Relative Strength Index (RSI) ChartProstatype Genomics AB Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Prostatype Genomics AB. The current phase is Correction in bear market.

The long score for the Stochastic Oscillator is 4/6.
The longshort score for the Stochastic Oscillator is 4/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Prostatype Genomics AB price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Prostatype Genomics AB Daily Stochastic Oscillator ChartProstatype Genomics AB Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Prostatype Genomics AB. The current cci is 32.68.

Prostatype Genomics AB Daily Commodity Channel Index (CCI) ChartProstatype Genomics AB Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Prostatype Genomics AB. The current cmo is 15.10.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Prostatype Genomics AB Daily Chande Momentum Oscillator (CMO) ChartProstatype Genomics AB Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Prostatype Genomics AB. The current willr is -43.75.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Prostatype Genomics AB is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Prostatype Genomics AB Daily Williams %R ChartProstatype Genomics AB Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Prostatype Genomics AB.

Prostatype Genomics AB Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Prostatype Genomics AB. The current atr is 0.00805572.

Prostatype Genomics AB Daily Average True Range (ATR) ChartProstatype Genomics AB Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Prostatype Genomics AB. The current obv is -46,216,038.

Prostatype Genomics AB Daily On-Balance Volume (OBV) ChartProstatype Genomics AB Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Prostatype Genomics AB. The current mfi is 34.74.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Prostatype Genomics AB Daily Money Flow Index (MFI) ChartProstatype Genomics AB Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Prostatype Genomics AB.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-09STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-10STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-13STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-17STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-21STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-11-23MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-11-24MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-11-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-01DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-12-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-05STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-07STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-12STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-19STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-20CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-21SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-22CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-27SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-28ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-29RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-03CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-04CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-05CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-16WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-17SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-19MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-23DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-29MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-09MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-12STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-13STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-14CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-19WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-22CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-23STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-26CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-01CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-06CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-07WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-11SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-12MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-19CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-22STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-25CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-26MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-28STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside

6.3. Candlestick Patterns

Prostatype Genomics AB Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Prostatype Genomics AB based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5054.792
Ma 20Greater thanMa 500.058
Ma 50Greater thanMa 1000.052
Ma 100Greater thanMa 2000.060
OpenGreater thanClose0.054
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Prostatype Genomics AB with someone you think should read this too:
  • Are you bullish or bearish on Prostatype Genomics AB? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Prostatype Genomics AB? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Prostatype Genomics AB

I send you an email if I find something interesting about Prostatype Genomics AB.


Comments

How you think about this?

Leave a comment

Stay informed about Prostatype Genomics AB.

Receive notifications about Prostatype Genomics AB in your mailbox!